Alkaloid constituents from flower buds and leaves of sacred lotus (Nelumbo nucifera, Nymphaeaceae) with melanogenesis inhibitory activity in B16 melanoma cells

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 3, 2013, Pages 779-787

  Nakamura, Seikou ^a   Nakashima, Souichi ^a   Tanabe, Genzo ^b   Oda, Yoshimi ^a   Yokota, Nami ^a   Fujimoto, Katsuyoshi ^a   Matsumoto, Takahiro ^a   Sakuma, Rika ^a   Ohta, Tomoe ^a   Ogawa, Keiko ^a   Nishida, Shino ^a   Miki, Hisako ^a   Matsuda, Hisashi ^a   Muraoka, Osamu ^b   Yoshikawa, Masayuki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Aporphine type alkaloid; Benzylisoquinoline type alkaloid; Medicinal flower; Melanogenesis inhibitor; N Methylasimilobine N oxide; Nelumbo nucifera

Indexed keywords

2 HYDROXY 1 METHOXY 6A,7 DEHYDROAPORPHINE; 5 NORNUCIFERINE; ALKALOID; ARMEPAVINE; ASIMILOBINE; ASTRAGALIN; CATECHIN; DEHYDRONUCIFERINE; HYPERIN; ISOQUERCITRIN; ISORHAMNETIN 3 O BETA DEXTRO GLUCOPYRANOSIDE; LIRINIDINE; LYSICAMINE; MESSENGER RNA; METHANOL; MONOPHENOL MONOOXYGENASE; N METHYLASIMILOBINE; N METHYLASIMILOBINE N OXIDE; NELUMBO NUCIFERA EXTRACT; NORNUCIFERINE; NUCIFERINE; NUCIFERINE N OXIDE; PALMITIC ACID; PRONUCIFERIN; SITOSTEROL; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; FLOWER; IC 50; MELANOCYTE; MELANOGENESIS; MELANOMA CELL; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PLANT LEAF; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLOWERS; HUMANS; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR STRUCTURE; NELUMBO; PLANT LEAVES; STRUCTURE-ACTIVITY RELATIONSHIP;

MURINAE; NELUMBO NUCIFERA; NYMPHAEACEAE;

EID: 84872363720     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.11.038     Document Type: Article

References (52)

1. S. Nakamura, K. Fujimoto, S. Nakashima, T. Matsumoto, T. Miura, K. Uno, H. Matsuda, and M. Yoshikawa Chem. Pharm. Bull. 60 2012 752
2. P.K. Mukherjee, D. Mukherjee, A.K. Maji, S. Rai, and M. Heinrich J. Pharm. Pharmacol. 61 2009 407
3. H. Matsuda, S. Nakashima, Y. Oda, S. Nakamura, and M. Yoshikawa Bioorg. Med. Chem. 17 2009 6048
4. S. Nakashima, H. Matsuda, Y. Oda, S. Nakamura, F. Xu, and M. Yoshikawa Bioorg. Med. Chem. 18 2010 2337
5. S. Nakamura, G. Chen, S. Nakashima, H. Matsuda, Y. Pei, and M. Yoshikawa Chem. Pharm. Bull. 58 2010 690
6. K. Fujimoto, S. Nakamura, S. Nakashima, T. Matsumoto, K. Uno, T. Ohta, T. Miura, H. Matsuda, and M. Yoshikawa Chem. Pharm. Bull. 60 2012 1188
7. S. Nakamura, T. Moriura, S. Park, K. Fujimoto, T. Matsumoto, T. Ohta, H. Matsuda, and M. Yoshikawa J. Nat. Prod. 75 2012 1425
8. T. Morikawa, X. Li, E. Nishida, S. Nakamura, K. Ninomiya, H. Matsuda, M. Hamao, O. Muraoka, T. Hayakawa, and M. Yoshikawa Chem. Pharm. Bull. 59 2011 889
9. H. Matsuda, S. Nakamura, K. Fujimoto, R. Moriuchi, Y. Kimura, N. Ikoma, Y. Hata, O. Muraoka, and M. Yoshikawa Chem. Pharm. Bull. 58 2010 1617
10. T. Morikawa, L.B. Wang, K. Ninomiya, S. Nakamura, H. Matsuda, O. Muraoka, L.J. Wu, and M. Yoshikawa Chem. Pharm. Bull. 57 2009 853
11. T. Morikawa, L.B. Wang, S. Nakamura, K. Ninomiya, E. Yokoyama, H. Matsuda, O. Muraoka, L.J. Wu, and M. Yoshikawa Chem. Pharm. Bull. 57 2009 361
12. S. Nakamura, Y. Okazaki, K. Ninomiya, T. Morikawa, H. Matsuda, and M. Yoshikawa Chem. Pharm. Bull. 56 2008 1704
13. Y. Xie, T. Morikawa, K. Ninomiya, K. Imura, O. Muraoka, D. Yuan, and M. Yoshikawa Chem. Pharm. Bull. 56 2008 1628
14. M. Yoshikawa, X. Li, E. Nishida, S. Nakamura, H. Matsuda, O. Muraoka, and T. Morikawa Chem. Pharm. Bull. 56 2008 559
15. M. Yoshikawa, T. Morikawa, Y. Asao, E. Fujiwara, S. Nakamura, and H. Matsuda Chem. Pharm. Bull. 55 2007 606
16. M. Yoshikawa, S. Nakamura, Y. Kato, K. Matsuhira, and H. Matsuda Chem. Pharm. Bull. 55 2007 598
17. M. Yoshikawa, F. Xu, T. Morikawa, Y. Pongpiriyadacha, S. Nakamura, Y. Asao, A. Kumahara, and H. Matsuda Chem. Pharm. Bull. 55 2007 308
18. T. Morikawa, O. Muraoka, and M. Yoshikawa Yakugaku Zasshi 130 2010 673
19. V.J. Hearing, A.M. Körner, and J.M. Pawelek J. Invest. Dermatol. 79 1982 16
20. V.J. Hearing, and M. Jiménez Int. J. Biochem. 19 1987 1141
21. G. Prota Med. Res. Rev. 8 1988 525
22. T. Kuzumaki, A. Matsuda, K. Wakamatsu, S. Ito, and K. Ishikawa Exp. Cell Res. 207 1993 33
23. M. Tomita, Y. Watanabe, M. Tomita, and H. Furukawa Yakugaku Zasshi 81 1961 469
24. L.M. Jackman, J.C. Trewella, J.L. Moniot, M. Shamma, R.L. Stephens, E. Wenkert, M. Leboeuf, and A. Cave J. Nat. Prod. 42 1979 437
25. M. Lafrance, N. Blaquière, and K. Fagnou Eur. J. Org. Chem. 2007 811
26. S.T. Lu, Y.C. Wu, and S.P. Leou J. Chin. Chem. Soc. 34 1987 33
27. The absolute configuration of the methyl group of three was not decided. Therefore, the configuration was clarified by NOESY experiment and the structure was shown in Figure 1.
28. Z. Zheng, M. Wang, D. Wang, W. Duan, X. Wang, and C. Zheng J. Chromatogr., B 878 2010 1647
29. N. Kashiwaba, M. Ono, J. Toda, H. Suzuki, and T. Sano J. Nat. Prod. 63 2000 477
30. M. Tomita, Y. Watanabe, and H. Furukawa Yakugaku Zasshi 85 1965 77
31. R. Ahmad, J.M. Saa, and M.P. Cava J. Org. Chem. 42 1977 1228
32. G.D. Cuny Tetrahedron Lett. 44 2003 8149
33. A. Venkateswarlu, and M.P. Cava Tetrahedron: Asymmetry 32 1976 2079
34. H. Wu, B. Liu, W. Wang, and R. Shi Zhongcaoyao 41 2010 514
35. Z. Zhang, H.N. ElSohly, M.R. Jacob, D.S. Pasco, L.A. Walker, and A.M. Clark J. Nat. Prod. 65 2002 856
36. M. Tomita, Y. Watanabe, and H. Furukawa Yakugaku Zasshi 81 1961 1644
37. V. Fajardo, M. Araya, P. Cuadra, A. Oyarzun, A. Gallardo, M. Cueto, A.R. Diaz-Marrero, J. Darias, L. Villarroel, C. Álvarez, Y. Mora-Pérez, and P. Joseph-Nathan J. Nat. Prod. 72 2009 1355
38. K.R. Markham, B. Ternai, R. Stanley, H. Geiger, and T.J. Mabry Tetrahedron: Asymmetry 34 1977 1389
39. L.O.A. Manguro, I. Ugi, P. Lemmen, and R. Hermann Phytochemistry 64 2003 891
40. Y.S. Lee, S. Lee, H.S. Lee, B.-K. Kim, K. Ohuchi, and K.H. Shin Biol. Pharm. Bull. 28 2005 916
41. S. Lee, D.-S. Shin, K.-B. Oh, and K.H. Shin Arch. Pharm. Res. 26 2003 40
42. 13C NMR spectra was assigned with the aid of distortionless enhancement by polarization transfer (DEPT), double quantum filter correlation spectroscopy (DQF COSY), heteronuclear multiple quantum coherence spectroscopy (HMQC), and heteronuclear multiple bond connectivity spectroscopy (HMBC) experiments.
43. The weak inhibitory activity of 8 seems to be attributable to its stability.
44. M. Lafrance, N. Blaquière, and K. Fagnou Chem. Commun. 2004 2874
45. X.-X. Shi, F. Ni, H.-X. Shang, M.-L. Yan, and J.Q. Su Tetrahedron: Asymmetry 17 2006 2210
46. J. Kunitomo, C. Yamamoto, and T. Otsuki Yakugaku Zasshi 84 1964 1100
47. Y.-G. Si, M.P. Gardner, F.I. Tarazi, R.J. Baldessarini, and J.L. Neumeyer Bioorg. Med. Chem. Lett. 18 2008 3971
48. R.S. Dothager, K.S. Putt, B.J. Allen, B.J. Leslie, V. Nesterenko, and P.J. Hergenrother J. Am. Chem. Soc. 127 2005 8686
49. U.R. Mach, A.E. Hackling, S. Perachon, S. Ferry, C.G. Wermuth, J.-C. Schwartz, P. Sokoloff, and H. Stark ChemBioChem 5 2004 508
50. G.J. Meuzelaar, L. Maat, and R.A. Sheldon Tetrahedron: Asymmetry 55 1999 4481
51. T. Shinohara, A. Takeda, J. Toda, N. Terasawa, and T. Sano Heterocycles 46 1997 555
52. C. Bertolotto, R. Busca, P. Abbe, K. Bille, E. Aberdam, J.-P. Ortonne, and R. Ballotti Mol. Cell Biol. 18 1998 694